Loading...
Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
BACKGROUND: Immune checkpoint inhibitors (ICIs) are an important treatment modality that must be considered for patients with lung adenocarcinoma (LUAD). However, ICIs are effective only in some of these patients. Therefore, identifying biomarkers that accurately predict the prognosis of patients wi...
Na minha lista:
| Udgivet i: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7434857/ https://ncbi.nlm.nih.gov/pubmed/32903385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.01213 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|